Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab intrapleural therapy for malignant pleural effusion in advanced NSCLC
ChiCTR2300076125Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC) and malignant pleural effusion (MPE), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Pleural effusion control rate. Started Oct 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)malignant pleural effusion (MPE)
Beyond the preview
Go deeper on ChiCTR2300076125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076125.